Ensysce Biosciences closes $4M convertible preferred stock financing with up to $20M available

Ensysce Biosciences, Inc.

Closed $4M convertible preferred stock financing; up to $16M additional available in future tranches over 24 months.
Conversion price fixed at $2.50/share; 50% warrant coverage exercisable at same price for five years.
Proceeds to accelerate Phase 3 clinical development of PF614, a novel abuse-resistant analgesic.
Series B preferred pays 4% annual dividend (8% on triggering events); stated value $1,100 per share.
Net proceeds from the offerings estimated at ~$3.6 million for general corporate purposes and working capital.

item 1.01 item 3.02 item 5.03 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.95

Ensysce Biosciences, Inc. issued 2,487 unregistered shares of Preferred Shares convertible into 1,094,078 shares of Common Stock of preferred stock to institutional investor for per share purchase price of $1,000, stated value $1,100.

Security: preferred stock
Shares: 2,487 unregistered shares of Preferred Shares convertible into 1,094,078 shares of Common Stock
Purchaser: institutional investor
Consideration: per share purchase price of $1,000, stated value $1,100

Exact text from the filing

investor held the number of shares of common stock acquirable upon a complete exercise of the Warrant. In the Offerings, the per share purchase price of the Preferred Stock is $1,000 with a stated value of $1100, and the conversion price per share of Common Stock is $2.50, subject to adjustment. In no event will the total cumulative number of shares of common

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Ensysce Biosciences, Inc.: Filed Certificate of Designation of Series B Preferred Stock, fixing designations, preferences, limitations and rights of the preferred stock (effective 2025-11-14).

Change: charter amendment
Effective: 2025-11-14

Exact text from the filing

On November 14, 2025, the Company filed a Certificate of Designation of Series B Preferred Stock, including a Certificate of Correction (together the “ Certificate of Designation ”) with the Secretary of State of the State of Delaware.

View on SEC.gov

Browse all equity issuances →

Ensysce Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-023933

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.